Literature DB >> 1674157

11C-SCH 39166, a selective ligand for visualization of dopamine-D1 receptor binding in the monkey brain using PET.

G Sedvall1, L Farde, A Barnett, H Hall, C Halldin.   

Abstract

The new selective D1-dopamine receptor antagonist SCH 39166 was labelled with the positron emitting isotope 11C and used as ligand for visualization of dopamine-D1 receptor binding in Cynomolgus monkeys by PET. After intravenous administration of the ligand a marked uptake of radioactivity was recorded in the D1-dopamine receptor-rich striatum and neocortex but not in the dopamine receptor-poor cerebellum. The uptake of radioactivity in striatum and neocortex was markedly displaced after the intravenous injection of a high dose of the D1-dopamine receptor antagonist SCH 23390 but not after the 5-HT2 receptor antagonist ketanserine. 11C-SCH 39166 should be a useful tool to explore D1-dopamine receptor characteristics in the living human brain by PET.

Entities:  

Mesh：

Substances：

Year:  1991        PMID： 1674157     DOI： 10.1007/bf02244195

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN： 0033-3158            Impact factor:   4.530


  12 in total

Review 1.  Multiple receptors for dopamine.

Authors:  J W Kebabian; D B Calne
Journal:  Nature       Date:  1979-01-11       Impact factor: 49.962

2.  Pharmacological profile of SCH39166: a dopamine D1 selective benzonaphthazepine with potential antipsychotic activity.

Authors:  R E Chipkin; L C Iorio; V L Coffin; R D McQuade; J G Berger; A Barnett
Journal:  J Pharmacol Exp Ther       Date:  1988-12       Impact factor: 4.030

3.  Preparation of 11C-labelled SCH 23390 for the in vivo study of dopamine D-1 receptors using positron emission tomography.

Authors:  C Halldin; S Stone-Elander; L Farde; E Ehrin; K J Fasth; B Långström; G Sedvall
Journal:  Int J Rad Appl Instrum A       Date:  1986

Review 4.  Drugs acting on brain dopamine receptors: a conceptual re-evaluation five years after the first selective D-1 antagonist.

Authors:  J L Waddington; K M O'Boyle
Journal:  Pharmacol Ther       Date:  1989       Impact factor: 12.310

5.  Human dopamine receptor subtypes--in vitro binding analysis using 3H-SCH 23390 and 3H-raclopride.

Authors:  H Hall; L Farde; G Sedvall
Journal:  J Neural Transm       Date:  1988       Impact factor: 3.575

6.  Dopamine D1-receptor binding in the living human brain.

Authors:  G Sedvall; L Farde; S Stone-Elander; C Halldin
Journal:  Adv Exp Med Biol       Date:  1986       Impact factor: 2.622

7.  SCH 23390 - the first selective dopamine D-1 antagonist.

Authors:  J Hyttel
Journal:  Eur J Pharmacol       Date:  1983-07-15       Impact factor: 4.432

8.  Characterization of the binding of 3H-SCH 23390, a selective D-1 receptor antagonist ligand, in rat striatum.

Authors:  W Billard; V Ruperto; G Crosby; L C Iorio; A Barnett
Journal:  Life Sci       Date:  1984-10-29       Impact factor: 5.037

9.  SCH 23390, a potential benzazepine antipsychotic with unique interactions on dopaminergic systems.

Authors:  L C Iorio; A Barnett; F H Leitz; V P Houser; C A Korduba
Journal:  J Pharmacol Exp Ther       Date:  1983-08       Impact factor: 4.030

10.  PET analysis of human dopamine receptor subtypes using 11C-SCH 23390 and 11C-raclopride.

Authors:  L Farde; C Halldin; S Stone-Elander; G Sedvall
Journal:  Psychopharmacology (Berl)       Date:  1987       Impact factor: 4.530
View more
  8 in total

Review 1.  Pharmacology of signaling induced by dopamine D(1)-like receptor activation.

Authors:  Ashiwel S Undieh
Journal:  Pharmacol Ther       Date:  2010-06-12       Impact factor: 12.310

2.  Probing cortical dopamine function in schizophrenia: what can D1 receptors tell us?

Authors:  Anissa Abi-Dargham
Journal:  World Psychiatry       Date:  2003-10       Impact factor: 49.548

Review 3.  Tracers for metabolic imaging of brain and heart. Radiochemistry and radiopharmacology.

Authors:  G Stöcklin
Journal:  Eur J Nucl Med       Date:  1992

4.  PET examination of [11C]NNC 687 and [11C]NNC 756 as new radioligands for the D1-dopamine receptor.

Authors:  P Karlsson; L Farde; C Halldin; C G Swahn; G Sedvall; C Foged; K T Hansen; B Skrumsager
Journal:  Psychopharmacology (Berl)       Date:  1993       Impact factor: 4.530

5.  An open trial of the D1 antagonist SCH 39166 in six cases of acute psychotic states.

Authors:  R de Beaurepaire; A Labelle; D Naber; B D Jones; T R Barnes
Journal:  Psychopharmacology (Berl)       Date:  1995-10       Impact factor: 4.530

6.  Evaluation of SCH 39166 as PET ligand for central D1 dopamine receptor binding and occupancy in man.

Authors:  P Karlsson; G Sedvall; C Halldin; C G Swahn; L Farde
Journal:  Psychopharmacology (Berl)       Date:  1995-10       Impact factor: 4.530

7.  Lack of apparent antipsychotic effect of the D1-dopamine receptor antagonist SCH39166 in acutely ill schizophrenic patients.

Authors:  P Karlsson; L Smith; L Farde; C Härnryd; G Sedvall; F A Wiesel
Journal:  Psychopharmacology (Berl)       Date:  1995-10       Impact factor: 4.530

Review 8.  Molecular Imaging of Opioid and Dopamine Systems: Insights Into the Pharmacogenetics of Opioid Use Disorders.

Authors:  Jamie A Burns; Danielle S Kroll; Dana E Feldman; Christopher Kure Liu; Peter Manza; Corinde E Wiers; Nora D Volkow; Gene-Jack Wang
Journal:  Front Psychiatry       Date:  2019-09-18       Impact factor: 4.157
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.